Non-specific effects of standard measles vaccine at 4.5 and 9 months of age on childhood mortality: randomised controlled trial

Abstract

Objective To examine in a randomised trial whether a 25% difference in mortality exists between 4.5 months and 3 years of age for children given two standard doses of Edmonston-Zagreb measles vaccines at 4.5 and 9 months of age compared with those given one dose of measles vaccine at 9 months of age (current policy). Design Randomised controlled trial. Setting The Bandim Health Project, Guinea-Bissau, which maintains a health and demographic surveillance system in an urban area. Participants 6648 children aged 4.5 months of age who had received three doses of diphtheria-tetanus-pertussis vaccine at least four weeks before enrolment. A large proportion of the children (80%) had previously taken part in randomised trials of neonatal vitamin A supplementation. Intervention Children were randomised to receive Edmonston-Zagreb measles vaccine at 4.5 and 9 months of age (group A), no vaccine at 4.5 months and Edmonston-Zagreb measles vaccine at 9 months of age (group B), or no vaccine at 4.5 months and Schwarz measles vaccine at 9 months of age (group C). Mainoutcomemeasure Mortality rate ratio between 4.5 and 36 months of age for group A compared with groups B and C. Secondary outcomes tested the hypothesis that the beneficial effect was stronger in the 4.5 to 9 months age group, in girls, and in the dry season, but the study was not powered to test whether effects differed significantly between subgroups. Results In the intention to treat analysis of mortality between 4.5 and 36 months of age the mortality rate ratio of children who received two doses of Edmonston-Zagreb vaccine at 4.5 and 9 months of age compared with those who received a single dose of Edmonston-Zagreb vaccine or Schwarz vaccine at 9 months of age was 0.78 (95% confidence interval 0.59 to 1.05). In the analyses of secondary outcomes, the intention to treat mortality rate ratio was 0.67 (0.38 to 1.19) between 4.5 and 9 months and 0.83 (0.83 to 1.16) between 9 and 36 months of age. The effect on mortality between 4.5 and 36 months of age was significant for girls (intention to treat mortality rate ratio 0.64 (0.42 to 0.98)), although this was not significantly different from the effect in boys (0.95 (0.64 to 1.42)) (interaction test, P=0.18). The effect did not differ between the dry season and the rainy season. As neonatal vitamin A supplementation is not WHO policy, the analyses were done separately for the 3402 children who did not receive neonatal vitamin A. In these children, the two dose Edmonston-Zagreb measles vaccine schedule was associated with a significantly lower mortality between 4.5 and 36 months of age (intention to treat mortality rate ratio 0.59 (0.39 to 0.89)). The effect was again significant for girls but not statistically significant from the effect in boys. When measles cases were censored, the intention to treat mortality rate ratio was 0.65 (0.43 to 0.99). Conclusions Although the overall effect did not reach statistical significance, the results may indicate that a two dose schedule with Edmonston-Zagreb measles vac...

High-dose Vitamin A With Vaccination After 6 Months of Age: A Randomized Trial

“…22,23 We recently observed that neonatal VAS followed by 3 doses of DTP and an early MV was particularly harmful for boys. 39 Thus, the combination of VAS and several vaccines may not benefit boys. In the present trial, we were not able to confirm the observation that VAS provided with DTP was particularly bad for girls, but it should be noted that at least one-third of the DTP-vaccinated children received MV during follow-up.…”

Non-specific and sex-differential effects of routine vaccines: What evidence is needed to take these effects into consideration in low-income countries?

“…12 Since the HTMV was fully protective against measles, the HTMV incident provided conclusive evidence that vaccines may have unexpected negative NSE and that these NSE can be sex-differential. 21 and BCG. 33 We succeeded in testing the effect of MV by providing an additional MV at 4.5 months of age in a large randomized trial.…”

Research priorities for global measles and rubella control and eradication

“…In addition, transferred maternal antibodies from vaccine-induced protection rather than naturally acquired measles virus infection generally result in lower geometric mean titers that wane faster, leaving the infant unprotected in early infancy [23,24]. Few published reports exist documenting increased risk of measles in younger infants due to the loss of protection in infants in low income settings and among mothers with vaccine-induced immunity [25,26], and implications of receiving MCV1 at an early age [27,28]. Information is needed to understand the role of infants in sustaining measles virus transmission in these settings, and for development of vaccination strategies to achieve elimination, particularly as exposure to wild measles virus becomes rarer.…”